Compare Roundhill Magnificent Seven ETF (MAGS) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Roundhill Magnificent Seven ETF vs GeneDx Holdings Corp — how do they compare? Roundhill Magnificent Seven ETF trades at $73.73 (market cap $5.78B), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: Roundhill Magnificent Seven ETF is far larger — about 2.9× GeneDx Holdings Corp's market cap, and Roundhill Magnificent Seven ETF is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Roundhill Magnificent Seven ETF for 36 Days and GeneDx Holdings Corp for 19 Days on average.
| MAGS | WGS | |
|---|---|---|
Market Cap | $5.78B | $2.02B |
Volume | 4,410,665 | 734,640 |
Sector | Sector/Thematic | Health |
52-Week High | $73.90 | $167.51 |
52-Week Low | $55.39 | $34.51 |
Typical Hold Time | 36 Days | 19 Days |
Enterprise Value | — | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MAGS (Roundhill Magnificent Seven ETF) trades at $73.03, down 0.9% on the day but maintains a bullish technical outlook with strong moving average signals. The ETF provides equal-weighted exposure to seven mega-cap tech leaders, though it has underperformed the broader market in 2026 with only 2% year-to-date gains. Recent news highlights the ongoing debate about the Magnificent Seven's leadership role as AI spending shifts focus toward semiconductor companies.
The ETF faces near-term pressure from reduced tech dividends and buybacks, but long-term AI exposure remains compelling. Key risks include concentration in seven stocks and market rotation away from mega-caps. Technical support at $71-72 provides a cushion, while resistance at $74-75 represents the next challenge for bullish momentum.
GeneDx (WGS) trades at $67.73, down 1.17% today, showing mixed signals with bearish technical indicators but strong analyst support. The company reported Q2 2026 revenue of $114.4 million, beating expectations, and returned to adjusted profitability early. However, 2026 fundamentals show concerning trends with a net loss of $106 million and negative profit margins. Recent news highlights product innovations and leadership recognition, while technical analysis indicates the stock is trading near key support at $66.
The investment outlook presents a dichotomy between strong analyst conviction (90.9% buy ratings, $81 consensus target) and challenging fundamentals. While operational improvements and genomic testing growth offer potential upside, persistent losses and negative cash flow trends create significant execution risk. The stock's current position near support levels combined with oversold RSI readings suggests potential for near-term bounce, but sustainable gains require meaningful profitability improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Roundhill Magnificent Seven ETF
MAGS is an ETF that provides concentrated exposure to the seven technology-focused mega-cap companies often referred to as the 'Magnificent Seven' (Alphabet, Amazon, Apple, Meta, Microsoft, NVIDIA, and Tesla). The fund is designed to capture the performance of these market-leading stocks, which have been the primary drivers of market returns. It offers a simple way for investors to invest solely in this select group of high-growth technology companies.
Read more on MAGS →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
